Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05715047 · ClinicalTrials.gov registry record · NA

Intervention for Fatigue in HCT Recipients

A NA study of Hematologic Malignancy and Hematologic Cancer, sponsored by Massachusetts General Hospital.

Recruiting
Registry status
NA
Development phase
66
Enrollment target
1
Study location

NCT05715047 is a NA study of Hematologic Malignancy and Hematologic Cancer that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 66 participants, below the 227-participant average among 48 other Hematologic Malignancy trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05715047, a NA study of Hematologic Malignancy and Hematologic Cancer, is actively recruiting participants, sponsored by Massachusetts General Hospital.

RECRUITING
Registry status
NA
Development phase
66 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to assess whether a cognitive-behavioral therapy (CBT) for fatigue intervention is acceptable, feasible, and effective at managing fatigue and improving quality of life for patients following hematopoietic stem cell transplant (HCT).

Interventions

  • BEHAVIORAL Usual Care
  • BEHAVIORAL CBT for Fatigue

Study Locations (1)

Massachusetts

  • Massachusetts General Hospital Cancer Center - Boston

Trial Details

FieldValue
Enrollment Target 66 participants
Start Date 2023-11-29
Est. Completion 2026-09-01
Phase NA

Sponsor

Massachusetts General Hospital

2,032 total trials

What the Registry Record Tells You About NCT05715047

The ClinicalTrials.gov registry entry for NCT05715047 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 227-participant average among 48 other Hematologic Malignancy trials with a reported enrollment target (71% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Hematologic Malignancy appearing as the primary indexed condition, and to 2 interventions - of which Usual Care is the first listed.

NCT05715047 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT05715047 about?

NCT05715047 is a clinical study titled "Intervention for Fatigue in HCT Recipients". The purpose of this study is to assess whether a cognitive-behavioral therapy (CBT) for fatigue intervention is acceptable, feasible, and effective at managing fatigue and improving quality of life for patients following hematopoietic stem cell transplant (HCT).

What is the current status of trial NCT05715047?

This trial is currently recruiting. It is a NA study. The enrollment target is 66 participants. The study started on 2023-11-29. Estimated completion is 2026-09-01.

What conditions does trial NCT05715047 study?

This clinical trial studies the following conditions: Hematologic Malignancy, Hematologic Cancer.

What interventions are being tested in trial NCT05715047?

The interventions under investigation include: Usual Care (BEHAVIORAL), CBT for Fatigue (BEHAVIORAL).

Who is sponsoring clinical trial NCT05715047?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05715047 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hematologic Malignancy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.